Magellan Midstream Partners LP
Change company Symbol lookup
Select an option...
MMP Magellan Midstream Partners LP
ELTK Eltek Ltd
LE Lands End Inc
WING Wingstop Inc
PUMP ProPetro Holding Corp
CHK Chesapeake Energy Corp
SALM Salem Media Group Inc
UGAZ VelocityShares 3x Long Natural Gas ETN Linked to the S&P GSCI? Natural Gas Index ER
UBSI United Bankshares Inc
LTM LATAM Airlines Group SA

Energy : Oil, Gas & Consumable Fuels | Mid Cap Value
Company profile

Magellan Midstream Partners, L.P. is principally engaged in the transportation, storage and distribution of refined petroleum products and crude oil. The Company operates through three segments: refined products, crude oil and marine storage. As of December 31, 2016, its asset portfolio, including the assets of its joint ventures, consisted of its refined products segment, consisting 9,700-mile refined products pipeline system with 53 terminals, as well as 26 independent terminals not connected to its pipeline system and its 1,100-mile ammonia pipeline system; its crude oil segment, consisted of approximately 2,200 miles of crude oil pipelines and storage facilities with an aggregate storage capacity of approximately 26 million barrels, of which 16 million are used for contract storage, and its marine storage segment, consisted of five marine terminals located along coastal waterways with an aggregate storage capacity of approximately 26 million barrels.

Closing Price
Day's Change
-0.81 (-1.79%)
B/A Size
Day's High
Day's Low

10-day average volume:

Moderna plans to sell more than $1 billion in fresh stock after COVID-19 vaccine study success

4:32 pm ET May 18, 2020 (MarketWatch)

After announcing positive results of a study of its potential COVID-19 vaccine ( and seeing shares jump 20% to record highs Monday, Moderna Inc. (MRNA) announced after trading closed that it will sell more than $1 billion in fresh shares. Moderna said it plans to sell $1.25 billion worth of stock to fund manufacturing and distribution of its vaccine candidate, referred to as mRNA-1273, if it can receive regulatory approvals. Moderna announced Monday morning that a phase 1 study of its vaccine was able to produce COVID-19 antibodies, and the company has laid out plans for phase 2 and phase 3 trials in the coming months. Shares closed at a record high of $80 Monday, up more than 300% from the beginning of the year, though the stock sank 2.8% in after-hours trading Monday after Moderna announced the impending arrival of new shares. Morgan Stanley is leading the offering, and Moderna expects to offer an additional $187.5 million in shares for overallotment.

-Jeremy C. Owens; 415-439-6400;

(END) Dow Jones Newswires

May 18, 2020 16:32 ET (20:32 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.